I think management overestimated the ADAPT technology and possibly why it still haven't received regulatory approval in the Australia (country of origin), hence they spent a lot of capital on trying to make it successful to get AHZ into the $500M+ MC. Undoubtedly, they took this path for a year too long so it's now only a small revenue maker for AHZ, so they've changed their strategy and re-band to now a TAVR bio-tech start-up with ADAPT maybe able to cover most of their operation and administration cost and since TAVR is in clinical trial this mean a majority of this technology development has been costed except for the clinical trial cost which they can claim at least half on R&D rebate.
- Forums
- ASX - By Stock
- AVR
- Ann: Notice of Annual General Meeting/Proxy Form
Ann: Notice of Annual General Meeting/Proxy Form, page-26
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$12.56 |
Change
-0.740(5.56%) |
Mkt cap ! $265.4M |
Open | High | Low | Value | Volume |
$13.06 | $13.30 | $12.55 | $359.0K | 27.63K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 399 | $12.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.78 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 399 | 12.560 |
2 | 724 | 12.550 |
2 | 451 | 12.500 |
1 | 1000 | 12.350 |
1 | 80 | 12.300 |
Price($) | Vol. | No. |
---|---|---|
12.550 | 1193 | 2 |
12.600 | 47 | 1 |
12.780 | 500 | 1 |
12.800 | 500 | 1 |
13.000 | 793 | 2 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |